CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2171874, encodeId=607e21e18748c, content=网站进不去？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37b81645553, createdName=Abao123, createdTime=Wed Nov 29 16:37:35 CST 2023, time=2023-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=998172, encodeId=338d9981e2cc, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cabc1899183, createdName=ms3772869039115374, createdTime=Sat Jul 10 10:58:23 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088382, encodeId=db65108838283, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088381, encodeId=af361088381b9, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=487222, encodeId=978748e22245, content=我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Mar 12 14:30:00 CST 2012, time=2012-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469568, encodeId=15d64695682a, content=杂志名称：Cancer Biotherapy & Radiopharmaceuticals 杂志国家：美国 投稿年份：2007，2008各投1篇 审稿周期:不足三月 是否经历大小修：小修 从开始投稿到接受（拒稿）多长时间：三月多点 期间是否要求润色语言：没有要求 费用：完全免费 个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=radiopharmaceuticals, createdTime=Tue Dec 15 10:14:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849365, encodeId=8986849365bf, content=惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74455414066, createdName=ms8364037627693300, createdTime=Fri Jan 18 17:54:22 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=472310, encodeId=dbf34e2310a1, content=我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=allen, createdTime=Thu Oct 28 17:09:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484608, encodeId=5c3548460807, content=这个容易中，如果临床与基础结合的更容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71ba17440, createdName=zhouyunzhoush, createdTime=Sun Sep 25 21:06:00 CST 2011, time=2011-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484712, encodeId=4fd2484e129d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232c29526, createdName=lsy6910553, createdTime=Mon Oct 03 21:22:00 CST 2011, time=2011-10-03, status=1, ipAttribution=)]

2023-11-29 Abao123 来自广东省

网站进不去？

54 0

[GetPortalCommentsPageByObjectIdResponse(id=2171874, encodeId=607e21e18748c, content=网站进不去？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37b81645553, createdName=Abao123, createdTime=Wed Nov 29 16:37:35 CST 2023, time=2023-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=998172, encodeId=338d9981e2cc, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cabc1899183, createdName=ms3772869039115374, createdTime=Sat Jul 10 10:58:23 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088382, encodeId=db65108838283, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088381, encodeId=af361088381b9, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=487222, encodeId=978748e22245, content=我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Mar 12 14:30:00 CST 2012, time=2012-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469568, encodeId=15d64695682a, content=杂志名称：Cancer Biotherapy & Radiopharmaceuticals 杂志国家：美国 投稿年份：2007，2008各投1篇 审稿周期:不足三月 是否经历大小修：小修 从开始投稿到接受（拒稿）多长时间：三月多点 期间是否要求润色语言：没有要求 费用：完全免费 个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=radiopharmaceuticals, createdTime=Tue Dec 15 10:14:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849365, encodeId=8986849365bf, content=惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74455414066, createdName=ms8364037627693300, createdTime=Fri Jan 18 17:54:22 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=472310, encodeId=dbf34e2310a1, content=我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=allen, createdTime=Thu Oct 28 17:09:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484608, encodeId=5c3548460807, content=这个容易中，如果临床与基础结合的更容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71ba17440, createdName=zhouyunzhoush, createdTime=Sun Sep 25 21:06:00 CST 2011, time=2011-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484712, encodeId=4fd2484e129d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232c29526, createdName=lsy6910553, createdTime=Mon Oct 03 21:22:00 CST 2011, time=2011-10-03, status=1, ipAttribution=)]

2021-07-10 ms3772869039115374

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！

96 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2171874, encodeId=607e21e18748c, content=网站进不去？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37b81645553, createdName=Abao123, createdTime=Wed Nov 29 16:37:35 CST 2023, time=2023-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=998172, encodeId=338d9981e2cc, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cabc1899183, createdName=ms3772869039115374, createdTime=Sat Jul 10 10:58:23 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088382, encodeId=db65108838283, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088381, encodeId=af361088381b9, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=487222, encodeId=978748e22245, content=我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Mar 12 14:30:00 CST 2012, time=2012-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469568, encodeId=15d64695682a, content=杂志名称：Cancer Biotherapy & Radiopharmaceuticals 杂志国家：美国 投稿年份：2007，2008各投1篇 审稿周期:不足三月 是否经历大小修：小修 从开始投稿到接受（拒稿）多长时间：三月多点 期间是否要求润色语言：没有要求 费用：完全免费 个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=radiopharmaceuticals, createdTime=Tue Dec 15 10:14:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849365, encodeId=8986849365bf, content=惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74455414066, createdName=ms8364037627693300, createdTime=Fri Jan 18 17:54:22 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=472310, encodeId=dbf34e2310a1, content=我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=allen, createdTime=Thu Oct 28 17:09:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484608, encodeId=5c3548460807, content=这个容易中，如果临床与基础结合的更容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71ba17440, createdName=zhouyunzhoush, createdTime=Sun Sep 25 21:06:00 CST 2011, time=2011-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484712, encodeId=4fd2484e129d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232c29526, createdName=lsy6910553, createdTime=Mon Oct 03 21:22:00 CST 2011, time=2011-10-03, status=1, ipAttribution=)]

2021-12-27 桑晒麦拉

如何回复评审的意见？

72 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2171874, encodeId=607e21e18748c, content=网站进不去？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37b81645553, createdName=Abao123, createdTime=Wed Nov 29 16:37:35 CST 2023, time=2023-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=998172, encodeId=338d9981e2cc, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cabc1899183, createdName=ms3772869039115374, createdTime=Sat Jul 10 10:58:23 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088382, encodeId=db65108838283, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088381, encodeId=af361088381b9, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=487222, encodeId=978748e22245, content=我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Mar 12 14:30:00 CST 2012, time=2012-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469568, encodeId=15d64695682a, content=杂志名称：Cancer Biotherapy & Radiopharmaceuticals 杂志国家：美国 投稿年份：2007，2008各投1篇 审稿周期:不足三月 是否经历大小修：小修 从开始投稿到接受（拒稿）多长时间：三月多点 期间是否要求润色语言：没有要求 费用：完全免费 个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=radiopharmaceuticals, createdTime=Tue Dec 15 10:14:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849365, encodeId=8986849365bf, content=惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74455414066, createdName=ms8364037627693300, createdTime=Fri Jan 18 17:54:22 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=472310, encodeId=dbf34e2310a1, content=我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=allen, createdTime=Thu Oct 28 17:09:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484608, encodeId=5c3548460807, content=这个容易中，如果临床与基础结合的更容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71ba17440, createdName=zhouyunzhoush, createdTime=Sun Sep 25 21:06:00 CST 2011, time=2011-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484712, encodeId=4fd2484e129d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232c29526, createdName=lsy6910553, createdTime=Mon Oct 03 21:22:00 CST 2011, time=2011-10-03, status=1, ipAttribution=)]

2021-12-27 衣谷

什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？

88 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2171874, encodeId=607e21e18748c, content=网站进不去？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37b81645553, createdName=Abao123, createdTime=Wed Nov 29 16:37:35 CST 2023, time=2023-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=998172, encodeId=338d9981e2cc, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cabc1899183, createdName=ms3772869039115374, createdTime=Sat Jul 10 10:58:23 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088382, encodeId=db65108838283, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088381, encodeId=af361088381b9, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=487222, encodeId=978748e22245, content=我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Mar 12 14:30:00 CST 2012, time=2012-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469568, encodeId=15d64695682a, content=杂志名称：Cancer Biotherapy & Radiopharmaceuticals 杂志国家：美国 投稿年份：2007，2008各投1篇 审稿周期:不足三月 是否经历大小修：小修 从开始投稿到接受（拒稿）多长时间：三月多点 期间是否要求润色语言：没有要求 费用：完全免费 个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=radiopharmaceuticals, createdTime=Tue Dec 15 10:14:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849365, encodeId=8986849365bf, content=惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74455414066, createdName=ms8364037627693300, createdTime=Fri Jan 18 17:54:22 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=472310, encodeId=dbf34e2310a1, content=我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=allen, createdTime=Thu Oct 28 17:09:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484608, encodeId=5c3548460807, content=这个容易中，如果临床与基础结合的更容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71ba17440, createdName=zhouyunzhoush, createdTime=Sun Sep 25 21:06:00 CST 2011, time=2011-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484712, encodeId=4fd2484e129d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232c29526, createdName=lsy6910553, createdTime=Mon Oct 03 21:22:00 CST 2011, time=2011-10-03, status=1, ipAttribution=)]

2012-03-12 匿名用户

我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！

612 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2171874, encodeId=607e21e18748c, content=网站进不去？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37b81645553, createdName=Abao123, createdTime=Wed Nov 29 16:37:35 CST 2023, time=2023-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=998172, encodeId=338d9981e2cc, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cabc1899183, createdName=ms3772869039115374, createdTime=Sat Jul 10 10:58:23 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088382, encodeId=db65108838283, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088381, encodeId=af361088381b9, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=487222, encodeId=978748e22245, content=我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Mar 12 14:30:00 CST 2012, time=2012-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469568, encodeId=15d64695682a, content=杂志名称：Cancer Biotherapy & Radiopharmaceuticals 杂志国家：美国 投稿年份：2007，2008各投1篇 审稿周期:不足三月 是否经历大小修：小修 从开始投稿到接受（拒稿）多长时间：三月多点 期间是否要求润色语言：没有要求 费用：完全免费 个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=radiopharmaceuticals, createdTime=Tue Dec 15 10:14:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849365, encodeId=8986849365bf, content=惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74455414066, createdName=ms8364037627693300, createdTime=Fri Jan 18 17:54:22 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=472310, encodeId=dbf34e2310a1, content=我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=allen, createdTime=Thu Oct 28 17:09:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484608, encodeId=5c3548460807, content=这个容易中，如果临床与基础结合的更容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71ba17440, createdName=zhouyunzhoush, createdTime=Sun Sep 25 21:06:00 CST 2011, time=2011-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484712, encodeId=4fd2484e129d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232c29526, createdName=lsy6910553, createdTime=Mon Oct 03 21:22:00 CST 2011, time=2011-10-03, status=1, ipAttribution=)]

2009-12-15 radiopharmaceuticals

杂志名称：Cancer Biotherapy & Radiopharmaceuticals
杂志国家：美国
投稿年份：2007，2008各投1篇
审稿周期:不足三月
是否经历大小修：小修
从开始投稿到接受（拒稿）多长时间：三月多点
期间是否要求润色语言：没有要求
费用：完全免费
个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。

344 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2171874, encodeId=607e21e18748c, content=网站进不去？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37b81645553, createdName=Abao123, createdTime=Wed Nov 29 16:37:35 CST 2023, time=2023-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=998172, encodeId=338d9981e2cc, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cabc1899183, createdName=ms3772869039115374, createdTime=Sat Jul 10 10:58:23 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088382, encodeId=db65108838283, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088381, encodeId=af361088381b9, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=487222, encodeId=978748e22245, content=我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Mar 12 14:30:00 CST 2012, time=2012-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469568, encodeId=15d64695682a, content=杂志名称：Cancer Biotherapy & Radiopharmaceuticals 杂志国家：美国 投稿年份：2007，2008各投1篇 审稿周期:不足三月 是否经历大小修：小修 从开始投稿到接受（拒稿）多长时间：三月多点 期间是否要求润色语言：没有要求 费用：完全免费 个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=radiopharmaceuticals, createdTime=Tue Dec 15 10:14:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849365, encodeId=8986849365bf, content=惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74455414066, createdName=ms8364037627693300, createdTime=Fri Jan 18 17:54:22 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=472310, encodeId=dbf34e2310a1, content=我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=allen, createdTime=Thu Oct 28 17:09:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484608, encodeId=5c3548460807, content=这个容易中，如果临床与基础结合的更容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71ba17440, createdName=zhouyunzhoush, createdTime=Sun Sep 25 21:06:00 CST 2011, time=2011-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484712, encodeId=4fd2484e129d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232c29526, createdName=lsy6910553, createdTime=Mon Oct 03 21:22:00 CST 2011, time=2011-10-03, status=1, ipAttribution=)]

2019-01-18 ms8364037627693300

惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊

149 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2171874, encodeId=607e21e18748c, content=网站进不去？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37b81645553, createdName=Abao123, createdTime=Wed Nov 29 16:37:35 CST 2023, time=2023-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=998172, encodeId=338d9981e2cc, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cabc1899183, createdName=ms3772869039115374, createdTime=Sat Jul 10 10:58:23 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088382, encodeId=db65108838283, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088381, encodeId=af361088381b9, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=487222, encodeId=978748e22245, content=我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Mar 12 14:30:00 CST 2012, time=2012-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469568, encodeId=15d64695682a, content=杂志名称：Cancer Biotherapy & Radiopharmaceuticals 杂志国家：美国 投稿年份：2007，2008各投1篇 审稿周期:不足三月 是否经历大小修：小修 从开始投稿到接受（拒稿）多长时间：三月多点 期间是否要求润色语言：没有要求 费用：完全免费 个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=radiopharmaceuticals, createdTime=Tue Dec 15 10:14:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849365, encodeId=8986849365bf, content=惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74455414066, createdName=ms8364037627693300, createdTime=Fri Jan 18 17:54:22 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=472310, encodeId=dbf34e2310a1, content=我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=allen, createdTime=Thu Oct 28 17:09:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484608, encodeId=5c3548460807, content=这个容易中，如果临床与基础结合的更容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71ba17440, createdName=zhouyunzhoush, createdTime=Sun Sep 25 21:06:00 CST 2011, time=2011-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484712, encodeId=4fd2484e129d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232c29526, createdName=lsy6910553, createdTime=Mon Oct 03 21:22:00 CST 2011, time=2011-10-03, status=1, ipAttribution=)]

2010-10-28 allen

我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。

415 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2171874, encodeId=607e21e18748c, content=网站进不去？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37b81645553, createdName=Abao123, createdTime=Wed Nov 29 16:37:35 CST 2023, time=2023-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=998172, encodeId=338d9981e2cc, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cabc1899183, createdName=ms3772869039115374, createdTime=Sat Jul 10 10:58:23 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088382, encodeId=db65108838283, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088381, encodeId=af361088381b9, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=487222, encodeId=978748e22245, content=我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Mar 12 14:30:00 CST 2012, time=2012-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469568, encodeId=15d64695682a, content=杂志名称：Cancer Biotherapy & Radiopharmaceuticals 杂志国家：美国 投稿年份：2007，2008各投1篇 审稿周期:不足三月 是否经历大小修：小修 从开始投稿到接受（拒稿）多长时间：三月多点 期间是否要求润色语言：没有要求 费用：完全免费 个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=radiopharmaceuticals, createdTime=Tue Dec 15 10:14:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849365, encodeId=8986849365bf, content=惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74455414066, createdName=ms8364037627693300, createdTime=Fri Jan 18 17:54:22 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=472310, encodeId=dbf34e2310a1, content=我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=allen, createdTime=Thu Oct 28 17:09:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484608, encodeId=5c3548460807, content=这个容易中，如果临床与基础结合的更容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71ba17440, createdName=zhouyunzhoush, createdTime=Sun Sep 25 21:06:00 CST 2011, time=2011-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484712, encodeId=4fd2484e129d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232c29526, createdName=lsy6910553, createdTime=Mon Oct 03 21:22:00 CST 2011, time=2011-10-03, status=1, ipAttribution=)]

2011-09-25 zhouyunzhoush

这个容易中，如果临床与基础结合的更容易中

526 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2171874, encodeId=607e21e18748c, content=网站进不去？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37b81645553, createdName=Abao123, createdTime=Wed Nov 29 16:37:35 CST 2023, time=2023-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=998172, encodeId=338d9981e2cc, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2021.3.21投稿 2021.5.11收到一审意见，大修，3个审稿人，19个问题，不包括编辑格式意见 2021.5.25修回 2021.6.8二审意见收到，补充western完整胶片和统计学分析的结果 2021.6.9果断写撤稿信，为什么不一开始就要胶片，耽误这么长时间。做实验胶片没留好，是个教训。给大家提醒做western实验原始胶片要就好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cabc1899183, createdName=ms3772869039115374, createdTime=Sat Jul 10 10:58:23 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088382, encodeId=db65108838283, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088381, encodeId=af361088381b9, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=487222, encodeId=978748e22245, content=我等着文章出来毕业。请问大家从接受到出proof，再到上网，要多久时间？谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=612, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Mar 12 14:30:00 CST 2012, time=2012-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=469568, encodeId=15d64695682a, content=杂志名称：Cancer Biotherapy & Radiopharmaceuticals 杂志国家：美国 投稿年份：2007，2008各投1篇 审稿周期:不足三月 是否经历大小修：小修 从开始投稿到接受（拒稿）多长时间：三月多点 期间是否要求润色语言：没有要求 费用：完全免费 个人评述（感受或经验）：这个杂志的文章感觉还是比较容易接收的，目前投了2篇，几乎都是小修了一下就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=radiopharmaceuticals, createdTime=Tue Dec 15 10:14:00 CST 2009, time=2009-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849365, encodeId=8986849365bf, content=惨遭拒稿，理由就给我说觉得不合适他们期刊，欲哭无泪啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74455414066, createdName=ms8364037627693300, createdTime=Fri Jan 18 17:54:22 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=472310, encodeId=dbf34e2310a1, content=我的文章2010.10.18投的，一直都是under review的状态，看来审稿确实很慢，三个月能接收，别等了三个月给拒了，那就杯具了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=415, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=allen, createdTime=Thu Oct 28 17:09:00 CST 2010, time=2010-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484608, encodeId=5c3548460807, content=这个容易中，如果临床与基础结合的更容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71ba17440, createdName=zhouyunzhoush, createdTime=Sun Sep 25 21:06:00 CST 2011, time=2011-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484712, encodeId=4fd2484e129d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232c29526, createdName=lsy6910553, createdTime=Mon Oct 03 21:22:00 CST 2011, time=2011-10-03, status=1, ipAttribution=)]

2011-10-03 lsy6910553

审稿速度:3.0 | 投稿命中率:75.0
经验分享：我是2011年2月份投稿的，经历了一次小修，4月末就接收了，速度很快，8月11号文章就见刊了。

559 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务